Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study

Journal of Infection and Chemotherapy

Volumn 18, Issue 6, 2012, Pages 891-897

  Endo, Shigeatsu ^a   Suzuki, Yasushi ^a   Takahashi, Gaku ^a   Shozushima, Tatsuyori ^a   Ishikura, Hiroyasu ^b   Murai, Akira ^b   Nishida, Takeshi ^b   Irie, Yuhei ^b   Miura, Masanao ^c   Iguchi, Hironobu ^c   Fukui, Yasuo ^d   Tanaka, Kimiaki ^d   Nojima, Tsuyoshi ^d   Okamura, Yoshikazu ^e  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c Kariya Toyota General Hospital   (Japan)

^d Kochi Health Sciences Center   (Japan)

^e LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Infection; Presepsin; Procalcitonin; Sepsis; Soluble CD14 subtype

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; INTERLEUKIN 6; PRESEPSIN; PROCALCITONIN; UNCLASSIFIED DRUG; CALCITONIN; CD14 ANTIGEN; PROTEIN PRECURSOR;

ADOLESCENT; ADULT; AGED; BLOOD CULTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; ARTICLE; BACTEREMIA; BLOOD; MIDDLE AGED; NONPARAMETRIC TEST; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; BACTEREMIA; BIOLOGICAL MARKERS; CALCITONIN; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84880431630     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0435-2     Document Type: Article

References (16)

1. Meisner M. Pathobiochemistry and clinical use of procalcitonin. 2002;323(1-2):17-29.
2. Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother. 2005;11:152-9. (Pubitemid 40933683)
3. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother. 2008;14:244-9. (Pubitemid 351875922)
4. Endo S, Sato N, Suzuki Y, Kojika M, Takahashi G, Yamada Y, et al. Significance of measuring procalcitonin values for diagnosis of sepsis. J Jpn Soc Surg Infect 2007;4(3):112-120 (in Japanese)
5. Furusako S, Shirakawa K. Methods for detecting human low molecular weight CD14. United States patent 2008; US7465547 B2.
6. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009; US7608684 B2.
7. Naitoh K, Shirakawa K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST (PRESEPSIN): induction mechanism in the rabbit sepsis models. SEPSIS 2010, Poster P-19.
8. Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yamasaki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care. 2008;12(suppl 2):P194. doi: 10.1186/cc6415.
9. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11(5):234-8. (Pubitemid 41570019)
10. Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, et al. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Med Postgrad. 2010;48(1):46-50.
11. Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, et al. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad. 2010;48(1):19-24.
12. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764-9.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55.
14. Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem. 2008;375(1):144-6.
15. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412(23-24):2157-61.
16. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.